Fujifilm Irvine Scientific

Fujifilm Irvine Scientific (FISI), headquartered in Santa Ana, California, is a worldwide leader in the manufacture and supply of cell culture media, reagents, feeds, specialty chemicals, and single-use technologies for researchers and clinicians in the biopharmaceutical, cell therapy, and regenerative medicine markets. Founded in 1970 as Irvine Scientific, the company was acquired by JXTG Energy in 1987 before Fujifilm invested US$800 million to take ownership in 2018, establishing itself as a dominant force in the cell culture media and services market.

The company operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan, adhering to ISO and FDA regulations, and maintains a global sales and support network spanning the United States, Europe, and Asia. Its product portfolio supports customers developing and manufacturing biopharmaceuticals, cell and gene therapies, and human-induced pluripotent stem cell applications.

In a strategic shift, FISI divested its Medical Business Unit — covering IVF, infertility research, and cytogenetic analysis products — to Astorg, to focus investment on core bioproduction growth areas. As of January 1, 2026, FUJIFILM Irvine Scientific officially rebranded as FUJIFILM Biosciences, reflecting its expanded life sciences mandate built on 55 years of cell culture expertise.

Innovations in cell culture media formulation, bioprocess optimization, and advanced gene therapy manufacturing are directly relevant to this company, given its role as a critical supplier enabling the development and scale-up of next-generation biological treatments.